472 related articles for article (PubMed ID: 30390312)
1. CGRP, Amylin, Immunology, and Headache Medicine.
Taylor FR
Headache; 2019 Jan; 59(1):131-150. PubMed ID: 30390312
[TBL] [Abstract][Full Text] [Related]
2. Antigens and Antibodies in Disease With Specifics About CGRP Immunology.
Taylor FR
Headache; 2018 Nov; 58 Suppl 3():230-237. PubMed ID: 30187471
[TBL] [Abstract][Full Text] [Related]
3. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
[TBL] [Abstract][Full Text] [Related]
4. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
5. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
Yuan H; Spare NM; Silberstein SD
Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
[TBL] [Abstract][Full Text] [Related]
6. Migraine therapeutics differentially modulate the CGRP pathway.
Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
[TBL] [Abstract][Full Text] [Related]
7. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
8. Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor.
Hage La Cour S; Juhler K; Kogelman LJA; Olesen J; Klærke DA; Kristensen DM; Jansen-Olesen I
J Headache Pain; 2022 May; 23(1):59. PubMed ID: 35614383
[TBL] [Abstract][Full Text] [Related]
9. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
Hargreaves R; Olesen J
Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
[TBL] [Abstract][Full Text] [Related]
10. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
[TBL] [Abstract][Full Text] [Related]
11. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640
[TBL] [Abstract][Full Text] [Related]
12. The
González-Hernández A; Marichal-Cancino BA; García-Boll E; Villalón CM
CNS Neurol Disord Drug Targets; 2020; 19(5):344-359. PubMed ID: 32552657
[TBL] [Abstract][Full Text] [Related]
13. New Insights into the Regulation of CGRP-Family Receptors.
Gingell JJ; Hendrikse ER; Hay DL
Trends Pharmacol Sci; 2019 Jan; 40(1):71-83. PubMed ID: 30527443
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
de Vries T; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
16. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Edvinsson L; Haanes KA; Warfvinge K; Krause DN
Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors.
Garelja ML; Alexander TI; Bennie A; Nimick M; Petersen J; Walker CS; Hay DL
Br J Pharmacol; 2024 Jan; 181(1):142-161. PubMed ID: 37580864
[TBL] [Abstract][Full Text] [Related]
18. Effects of monoclonal antagonist antibodies on calcitonin gene-related peptide receptor function and trafficking.
Manoukian R; Sun H; Miller S; Shi D; Chan B; Xu C
J Headache Pain; 2019 Apr; 20(1):44. PubMed ID: 31039731
[TBL] [Abstract][Full Text] [Related]
19. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
Maasumi K; Michael RL; Rapoport AM
Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
[TBL] [Abstract][Full Text] [Related]
20. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P
J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
